Does the media refer more to EXEL or ABCL?

In the previous week, AbCellera Biologics had 3 more articles in the media than Exelixis. MarketBeat recorded 6 mentions for AbCellera Biologics and 3 mentions for Exelixis. Exelixis' average media sentiment score of 0.51 beat AbCellera Biologics' score of 0.11 indicating that Exelixis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exelixis 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AbCellera Biologics 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to ASND or ABCL?

In the previous week, AbCellera Biologics had 2 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 6 mentions for AbCellera Biologics and 4 mentions for Ascendis Pharma A/S. AbCellera Biologics' average media sentiment score of 0.11 beat Ascendis Pharma A/S's score of 0.00 indicating that AbCellera Biologics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascendis Pharma A/S 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral AbCellera Biologics 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to ABCL or SMMT?

In the previous week, Summit Therapeutics had 5 more articles in the media than AbCellera Biologics. MarketBeat recorded 11 mentions for Summit Therapeutics and 6 mentions for AbCellera Biologics. Summit Therapeutics' average media sentiment score of 0.44 beat AbCellera Biologics' score of 0.11 indicating that Summit Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AbCellera Biologics 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Summit Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor BBIO or ABCL?

In the previous week, BridgeBio Pharma had 7 more articles in the media than AbCellera Biologics. MarketBeat recorded 13 mentions for BridgeBio Pharma and 6 mentions for AbCellera Biologics. BridgeBio Pharma's average media sentiment score of 0.39 beat AbCellera Biologics' score of 0.11 indicating that BridgeBio Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Pharma 3 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral AbCellera Biologics 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor HALO or ABCL?

In the previous week, Halozyme Therapeutics had 5 more articles in the media than AbCellera Biologics. MarketBeat recorded 11 mentions for Halozyme Therapeutics and 6 mentions for AbCellera Biologics. Halozyme Therapeutics' average media sentiment score of 0.42 beat AbCellera Biologics' score of 0.11 indicating that Halozyme Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Halozyme Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral AbCellera Biologics 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

AbCellera Biologics (ABCL) Competitors

$12.83 -0.32 (-2.43%)

Closing price 04:00 PM Eastern

Extended Trading

$12.92 +0.09 (+0.70%)

As of 06:21 PM Eastern

Compare

ABCL vs. EXEL, ASND, SMMT, BBIO, and HALO

Should you buy AbCellera Biologics stock or one of its competitors? AbCellera Biologics's main competitors and comparable companies include Exelixis (EXEL), Ascendis Pharma A/S (ASND), Summit Therapeutics (SMMT), BridgeBio Pharma (BBIO), and Halozyme Therapeutics (HALO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does AbCellera Biologics compare to Exelixis?

Exelixis (NASDAQ:EXEL) and AbCellera Biologics (NASDAQ:ABCL) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, profitability, earnings, institutional ownership, analyst recommendations, valuation, dividends and media sentiment.

85.3% of Exelixis shares are owned by institutional investors. Comparatively, 61.4% of AbCellera Biologics shares are owned by institutional investors. 2.6% of Exelixis shares are owned by company insiders. Comparatively, 28.4% of AbCellera Biologics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Exelixis has a net margin of 35.33% compared to AbCellera Biologics' net margin of -248.83%. Exelixis' return on equity of 42.17% beat AbCellera Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exelixis	35.33%	42.17%	31.76%
AbCellera Biologics	-248.83%	-17.49%	-12.36%

Exelixis has higher revenue and earnings than AbCellera Biologics. AbCellera Biologics is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exelixis	$2.32B	6.23	$782.57M	$3.18	18.34
AbCellera Biologics	$75.13M	53.67	-$146.41M	-$0.54	N/A

Exelixis presently has a consensus price target of $50.29, indicating a potential downside of 13.79%. AbCellera Biologics has a consensus price target of $13.38, indicating a potential upside of 1.71%. Given AbCellera Biologics' stronger consensus rating and higher probable upside, analysts plainly believe AbCellera Biologics is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exelixis	1 Sell rating(s)	12 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.35
AbCellera Biologics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.67

Exelixis has a beta of 0.47, suggesting that its stock price is 53% less volatile than the broader market. Comparatively, AbCellera Biologics has a beta of 1.41, suggesting that its stock price is 41% more volatile than the broader market.

In the previous week, AbCellera Biologics had 3 more articles in the media than Exelixis. MarketBeat recorded 6 mentions for AbCellera Biologics and 3 mentions for Exelixis. Exelixis' average media sentiment score of 0.51 beat AbCellera Biologics' score of 0.11 indicating that Exelixis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exelixis	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AbCellera Biologics	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Exelixis beats AbCellera Biologics on 10 of the 16 factors compared between the two stocks.

How does AbCellera Biologics compare to Ascendis Pharma A/S?

Ascendis Pharma A/S (NASDAQ:ASND) and AbCellera Biologics (NASDAQ:ABCL) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, institutional ownership, profitability, media sentiment, risk and dividends.

Ascendis Pharma A/S presently has a consensus price target of $310.75, indicating a potential upside of 37.47%. AbCellera Biologics has a consensus price target of $13.38, indicating a potential upside of 1.71%. Given Ascendis Pharma A/S's stronger consensus rating and higher probable upside, analysts clearly believe Ascendis Pharma A/S is more favorable than AbCellera Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	3.00
AbCellera Biologics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.67

Ascendis Pharma A/S has a net margin of 70.99% compared to AbCellera Biologics' net margin of -248.83%. Ascendis Pharma A/S's return on equity of 32.54% beat AbCellera Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	70.99%	32.54%	7.71%
AbCellera Biologics	-248.83%	-17.49%	-12.36%

61.4% of AbCellera Biologics shares are held by institutional investors. 40.0% of Ascendis Pharma A/S shares are held by company insiders. Comparatively, 28.4% of AbCellera Biologics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

AbCellera Biologics has lower revenue, but higher earnings than Ascendis Pharma A/S. AbCellera Biologics is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$814.57M	17.31	-$258M	$12.89	17.54
AbCellera Biologics	$75.13M	53.67	-$146.41M	-$0.54	N/A

Ascendis Pharma A/S has a beta of 0.38, indicating that its share price is 62% less volatile than the broader market. Comparatively, AbCellera Biologics has a beta of 1.41, indicating that its share price is 41% more volatile than the broader market.

In the previous week, AbCellera Biologics had 2 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 6 mentions for AbCellera Biologics and 4 mentions for Ascendis Pharma A/S. AbCellera Biologics' average media sentiment score of 0.11 beat Ascendis Pharma A/S's score of 0.00 indicating that AbCellera Biologics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascendis Pharma A/S	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
AbCellera Biologics	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Ascendis Pharma A/S beats AbCellera Biologics on 10 of the 16 factors compared between the two stocks.

How does AbCellera Biologics compare to Summit Therapeutics?

AbCellera Biologics (NASDAQ:ABCL) and Summit Therapeutics (NASDAQ:SMMT) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, dividends, analyst recommendations, institutional ownership, valuation and profitability.

AbCellera Biologics has higher revenue and earnings than Summit Therapeutics. AbCellera Biologics is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AbCellera Biologics	$75.13M	53.67	-$146.41M	-$0.54	N/A
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.12	N/A

61.4% of AbCellera Biologics shares are held by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are held by institutional investors. 28.4% of AbCellera Biologics shares are held by company insiders. Comparatively, 83.5% of Summit Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summit Therapeutics has a net margin of 0.00% compared to AbCellera Biologics' net margin of -248.83%. AbCellera Biologics' return on equity of -17.49% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AbCellera Biologics	-248.83%	-17.49%	-12.36%
Summit Therapeutics	N/A	-168.94%	-141.92%

In the previous week, Summit Therapeutics had 5 more articles in the media than AbCellera Biologics. MarketBeat recorded 11 mentions for Summit Therapeutics and 6 mentions for AbCellera Biologics. Summit Therapeutics' average media sentiment score of 0.44 beat AbCellera Biologics' score of 0.11 indicating that Summit Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AbCellera Biologics	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Summit Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

AbCellera Biologics has a beta of 1.41, suggesting that its share price is 41% more volatile than the broader market. Comparatively, Summit Therapeutics has a beta of -1.51, suggesting that its share price is 251% less volatile than the broader market.

AbCellera Biologics presently has a consensus price target of $13.38, indicating a potential upside of 1.71%. Summit Therapeutics has a consensus price target of $28.61, indicating a potential upside of 65.27%. Given Summit Therapeutics' higher possible upside, analysts clearly believe Summit Therapeutics is more favorable than AbCellera Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AbCellera Biologics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.67
Summit Therapeutics	1 Sell rating(s)	8 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.53

Summary

AbCellera Biologics beats Summit Therapeutics on 8 of the 15 factors compared between the two stocks.

How does AbCellera Biologics compare to BridgeBio Pharma?

BridgeBio Pharma (NASDAQ:BBIO) and AbCellera Biologics (NASDAQ:ABCL) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends.

99.9% of BridgeBio Pharma shares are owned by institutional investors. Comparatively, 61.4% of AbCellera Biologics shares are owned by institutional investors. 14.2% of BridgeBio Pharma shares are owned by insiders. Comparatively, 28.4% of AbCellera Biologics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

AbCellera Biologics has lower revenue, but higher earnings than BridgeBio Pharma. AbCellera Biologics is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Pharma	$502.08M	26.07	-$724.93M	-$3.57	N/A
AbCellera Biologics	$75.13M	53.67	-$146.41M	-$0.54	N/A

BridgeBio Pharma has a net margin of -97.03% compared to AbCellera Biologics' net margin of -248.83%. BridgeBio Pharma's return on equity of 0.00% beat AbCellera Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Pharma	-97.03%	N/A	-61.19%
AbCellera Biologics	-248.83%	-17.49%	-12.36%

In the previous week, BridgeBio Pharma had 7 more articles in the media than AbCellera Biologics. MarketBeat recorded 13 mentions for BridgeBio Pharma and 6 mentions for AbCellera Biologics. BridgeBio Pharma's average media sentiment score of 0.39 beat AbCellera Biologics' score of 0.11 indicating that BridgeBio Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Pharma	3 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
AbCellera Biologics	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

BridgeBio Pharma presently has a consensus price target of $102.61, indicating a potential upside of 53.24%. AbCellera Biologics has a consensus price target of $13.38, indicating a potential upside of 1.71%. Given BridgeBio Pharma's stronger consensus rating and higher possible upside, research analysts clearly believe BridgeBio Pharma is more favorable than AbCellera Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	21 Buy rating(s)	0 Strong Buy rating(s)	2.83
AbCellera Biologics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.67

BridgeBio Pharma has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market. Comparatively, AbCellera Biologics has a beta of 1.41, indicating that its share price is 41% more volatile than the broader market.

Summary

BridgeBio Pharma beats AbCellera Biologics on 10 of the 17 factors compared between the two stocks.

How does AbCellera Biologics compare to Halozyme Therapeutics?

Halozyme Therapeutics (NASDAQ:HALO) and AbCellera Biologics (NASDAQ:ABCL) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, valuation, earnings, dividends and media sentiment.

In the previous week, Halozyme Therapeutics had 5 more articles in the media than AbCellera Biologics. MarketBeat recorded 11 mentions for Halozyme Therapeutics and 6 mentions for AbCellera Biologics. Halozyme Therapeutics' average media sentiment score of 0.42 beat AbCellera Biologics' score of 0.11 indicating that Halozyme Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Halozyme Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
AbCellera Biologics	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Halozyme Therapeutics has a net margin of 24.86% compared to AbCellera Biologics' net margin of -248.83%. Halozyme Therapeutics' return on equity of 260.98% beat AbCellera Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Halozyme Therapeutics	24.86%	260.98%	23.91%
AbCellera Biologics	-248.83%	-17.49%	-12.36%

Halozyme Therapeutics has higher revenue and earnings than AbCellera Biologics. AbCellera Biologics is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Halozyme Therapeutics	$1.40B	8.92	$316.89M	$3.35	32.75
AbCellera Biologics	$75.13M	53.67	-$146.41M	-$0.54	N/A

Halozyme Therapeutics has a beta of 0.88, suggesting that its share price is 12% less volatile than the broader market. Comparatively, AbCellera Biologics has a beta of 1.41, suggesting that its share price is 41% more volatile than the broader market.

Halozyme Therapeutics presently has a consensus price target of $91.20, suggesting a potential downside of 16.88%. AbCellera Biologics has a consensus price target of $13.38, suggesting a potential upside of 1.71%. Given AbCellera Biologics' higher possible upside, analysts plainly believe AbCellera Biologics is more favorable than Halozyme Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Halozyme Therapeutics	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.67
AbCellera Biologics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.67

97.8% of Halozyme Therapeutics shares are held by institutional investors. Comparatively, 61.4% of AbCellera Biologics shares are held by institutional investors. 2.5% of Halozyme Therapeutics shares are held by insiders. Comparatively, 28.4% of AbCellera Biologics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Halozyme Therapeutics beats AbCellera Biologics on 11 of the 16 factors compared between the two stocks.

Get AbCellera Biologics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABCL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ABCL vs. The Competition

Export

Metric	AbCellera Biologics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.93B	$3.85B	$7.19B	$13.38B
Dividend Yield	N/A	3.65%	2.53%	17.39%
P/E Ratio	-23.76	13.66	275.11	26.14
Price / Sales	52.36	1,230.78	634.05	106.73
Price / Cash	N/A	126.56	79.41	53.24
Price / Book	3.97	15.97	10.74	6.28
Net Income	-$146.41M	-$22.65M	$3.50B	$382.03M
7 Day Performance	-12.06%	-4.54%	-1.53%	-0.89%
1 Month Performance	12.25%	-12.55%	-6.72%	-5.31%
1 Year Performance	122.36%	13.33%	5.72%	0.76%

AbCellera Biologics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ABCL AbCellera Biologics	1.42 of 5 stars	$12.83 -2.4%	$13.38 +4.2%	+124.0%	$3.93B	$75.13M	N/A	562	Gap Up
EXEL Exelixis	2.8981 of 5 stars	$58.28 +0.6%	$50.29 -13.7%	+45.8%	$14.42B	$2.32B	18.30	1,077
ASND Ascendis Pharma A/S	4.4865 of 5 stars	$226.90 -0.2%	$310.75 +37.0%	+7.2%	$14.16B	$814.57M	17.60	1,189
SMMT Summit Therapeutics	2.8212 of 5 stars	$16.73 +0.2%	$28.61 +71.0%	-21.9%	$13.34B	N/A	N/A	265	Analyst Forecast
BBIO BridgeBio Pharma	3.2338 of 5 stars	$67.55 +1.0%	$102.61 +51.9%	+22.6%	$13.17B	$502.08M	N/A	839	News Coverage Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ABCL) was last updated on 10/7/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AbCellera Biologics (ABCL) Competitors

ABCL vs. EXEL, ASND, SMMT, BBIO, and HALO

How does AbCellera Biologics compare to Exelixis?

Summary

How does AbCellera Biologics compare to Ascendis Pharma A/S?

Summary

How does AbCellera Biologics compare to Summit Therapeutics?

Summary

How does AbCellera Biologics compare to BridgeBio Pharma?

Summary

How does AbCellera Biologics compare to Halozyme Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABCL vs. The Competition

AbCellera Biologics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

AbCellera Biologics (ABCL) Competitors

ABCL vs. EXEL, ASND, SMMT, BBIO, and HALO

How does AbCellera Biologics compare to Exelixis?

Do insiders & institutionals believe in EXEL or ABCL?

Is EXEL or ABCL more profitable?

Which has better earnings and valuation, EXEL or ABCL?

Do analysts rate EXEL or ABCL?

Which has more volatility & risk, EXEL or ABCL?

Does the media refer more to EXEL or ABCL?

Summary

How does AbCellera Biologics compare to Ascendis Pharma A/S?

Do analysts recommend ASND or ABCL?

Is ASND or ABCL more profitable?

Do institutionals & insiders believe in ASND or ABCL?

Which has preferable valuation & earnings, ASND or ABCL?

Which has more volatility and risk, ASND or ABCL?

Does the media refer more to ASND or ABCL?

Summary

How does AbCellera Biologics compare to Summit Therapeutics?

Which has preferable valuation and earnings, ABCL or SMMT?

Do institutionals & insiders believe in ABCL or SMMT?

Is ABCL or SMMT more profitable?

Does the media refer more to ABCL or SMMT?

Which has more risk and volatility, ABCL or SMMT?

Do analysts recommend ABCL or SMMT?

Summary

How does AbCellera Biologics compare to BridgeBio Pharma?

Do institutionals and insiders believe in BBIO or ABCL?

Which has higher valuation and earnings, BBIO or ABCL?

Is BBIO or ABCL more profitable?

Does the media favor BBIO or ABCL?

Do analysts recommend BBIO or ABCL?

Which has more risk & volatility, BBIO or ABCL?

Summary

How does AbCellera Biologics compare to Halozyme Therapeutics?

Does the media favor HALO or ABCL?

Is HALO or ABCL more profitable?

Which has stronger valuation & earnings, HALO or ABCL?

Which has more risk and volatility, HALO or ABCL?

Do analysts recommend HALO or ABCL?

Do institutionals and insiders have more ownership in HALO or ABCL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABCL vs. The Competition

AbCellera Biologics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools